US2003114521A1PendingUtilityA1
Oxamic acids and derivatives as thyroid receptor ligands
Priority: Mar 1, 1999Filed: Dec 20, 2002Published: Jun 19, 2003
Est. expiryMar 1, 2019(expired)· nominal 20-yr term from priority
A61P 3/04A61P 5/16A61P 9/12A61P 5/14A61P 3/10A61P 9/10A61P 43/00A61P 5/48A61P 9/06A61P 3/06A61P 9/00A61P 27/06A61P 25/24A61P 17/00A61P 19/00A61P 19/10C07C 2601/08C07D 295/096C07D 211/16C07D 295/192C07C 311/29C07D 215/20C07D 333/20C07D 217/06C07D 217/08C07C 2601/02C07D 317/58C07D 295/26C07C 2602/10C07C 2601/14C07C 317/22C07C 2602/42C07D 209/08C07D 211/14C07C 2602/08C07C 2601/04C07C 235/74C07D 215/08C07D 217/04
52
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides novel compounds of the Formula and prodrugs thereof, geometric and optical isomers thereof, and pharmaceutically acceptable salts of such compounds, prodrugs and isomers, wherein R 1 —R 8 and W are as described herein. Pharmaceutical compositions containing such compounds, prodrugs, isomers or pharmaceutically acceptable salts thereof, and methods, pharmaceutical compositions and kits for treating obesity, hyperlipidemia, glaucoma, cardiac arrhythmia, skin disorders, thyroid disease, hypothyroidism and related disorders and diseases such as diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression and osteoporosis are also provided.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A compound of the Formula
a prodrug thereof; a geometric or optical isomer thereof, or a pharmaceutically acceptable salt of said compound, said prodrug, or said isomer, wherein:
R 1 , R 2 and R 3 are each independently hydrogen, halogen, C 1-6 alkyl, trifluoromethyl, —CN, —OCF 3 or —OC 1-6 alkyl;
R 4 is hydrogen, C 1-12 alkyl optionally substituted with one to three substitutents independently selected from Group Z, C 2-12 alkenyl, halogen, —CN, aryl, heteroaryl, C 3-10 cycloalkyl, heterocycloalkyl, —S(O) 2 NR 9 R 10 , —C(O)NR 9 R 10 , —(C 1-6 alkyl)-NR 9 R 10 , —NR 9 C(O)R 10 , —NR 9 C(O)NR 9 R 10 , —NR 9 S(O) 2 R 10 , —(C 1-6 alkyl)—OR 11 , —OR 11 or —S(O) a R 12 , provided that, where R 5 is not fluoro, R 4 is —S(O) 2 NR 9 R 10 , —C(O)NR 9 R 10 , —(C 1-6 alkyl)-NR 9 R 10 , —NR 9 C(O)R 10 , —NR 9 C(O)NR 9 R 10 , —NR 9 S(O) 2 R 10 , —(C 1-6 alkyl)-OR 11 , —OR 11 or —S(O) a R 12 ;
or R 3 and R 4 may be taken together to form a carbocyclic ring A of the formula —(CH 2 ) b — or a heterocyclic ring A selected from the group consisting of —Q—(CH 2 ) c — and —(CH 2 ) j —Q—(CH 2 ) k — wherein Q is O, S or NR 17 , wherein said carbocyclic ring A and said heterocyclic ring A are each independently optionally substituted with one or more substituents independently selected from C 1-4 alkyl, halide or oxo;
R 5 is fluoro, hydroxy, C 1-4 alkoxy or OC(O)R 9 ;
or R 4 and R 5 may be taken together to form a heterocyclic ring B selected from the group consisting of —CR 9 ═CR 10 —NH—, —N═CR 9 —NH—, —CR 9 ═CH—O— and —CR 9 ═CH—S—;
R 6 is hydrogen, halogen, C 1-4 alkyl or trifluoromethyl;
R 7 is hydrogen or C 1-6 alkyl;
R 8 is —OR 9 or —NR 19 R 20 ;
R 9 and R 10 for each occurrence are independently (A) hydrogen, (B) C 1-12 alkyl optionally substituted with one or more substituents independently selected from Group V, (C) C 2-12 alkenyl, (D) C 3-10 cycloalkyl optionally substituted with one or more substituents independently selected from C 1-6 alkyl, C 2-5 alkynyl, C 3-10 cycloalkyl, —CN, —NR 13 R 14 , oxo, —OR 18 , —COOR 18 or aryl optionally substituted with X and Y, (E) aryl optionally substituted with X and Y, or (F) het optionally substituted with X and Y;
or R 9 and R 10 for any occurrence may be taken together to form a heterocyclic ring C optionally further containing a second heterogroup selected from the group consisting of —O—, —NR 13 — and —S—, and optionally further substituted with one or more substituents independently selected from C 1-5 alkyl, oxo, —NR 13 R 14 , —OR 18 , —C(O) 2 R 18 , —CN, —C(O) R 9 , aryl optionally substituted with X and Y, het optionally substituted with X and Y, C 5-6 spirocycloalkyl, and a carbocyclic ring B selected from the group consisting of 5-, 6-, 7- and 8-membered partially and fully saturated, and unsaturated carbocyclic rings, and including any bicyclic group in which said carbocyclic ring B is fused to a carbocyclic ring C selected from the group consisting of 5-, 6-, 7-and 8-membered partially and fully saturated, and unsaturated carbocyclic rings;
R 11 is C 1-12 alkyl optionally substituted with one or more substituents independently selected from Group V, C 2-12 alkenyl, C 3-10 cycloalkyl, trifluoromethyl, difluoromethyl, monofluoromethyl, aryl optionally substituted with X and Y, het optionally substituted with X and Y, —C(O)NR 9 R 10 or —C(O)R 9 ;
R 12 is C 1-12 alkyl optionally substituted with one or more substituents independently selected from Group V, C 2-12 alkenyl, C 3-10 cycloalkyl, aryl optionally substituted with X and Y, or het optionally substituted with X and Y;
R 13 and R 14 for each occurrence are independently hydrogen, C 1-6 alkyl, C 2-6 alkenyl, —(C 1-6 alkyl)-C 1-6 alkoxy, aryl optionally substituted with X and Y, het optionally substituted with X and Y, —(C 1-4 alkyl)-aryl optionally substituted with X and Y, —(C 1-4 alkyl)-heterocycle optionally substituted with X and Y, —(C 1-4 alkyl)-hydroxy, —(C 1-4 alkyl)-halo, —(C 1-4 alkyl)-poly-halo, —(C 1-4 alkyl)-CONR 15 R 16 or C 3-10 cycloalkyl;
R 15 and R 16 for each occurrence are independently hydrogen, C 1-6 alkyl, C 3-10 cycloalkyl or aryl optionally substituted with X and Y;
R 17 is hydrogen, C 1-6 alkyl, —COR 9 or —SO 2 R 9 ;
R 18 is hydrogen, C 1-6 alkyl, C 2-6 alkenyl, —(C 1-6 alkyl)-C 1-6 alkoxy, aryl optionally substituted with X and Y, het optionally substituted with X and Y, —(C 1-4 alkyl)-aryl optionally substituted with X and Y, —(C 1-4 alkyl)-heterocycle optionally substituted with X and Y, —(C 1-4 alkyl)-hydroxy, —(C 1-4 alkyl)-halo, —(C 1-4 alkyl)-poly-halo, —(C 1-4 alkyl)-CONR 15 R 16 , —(C 1-4 alkyl)-(C 1-4 alkoxy) or C 3-10 cycloalkyl;
R 19 is hydrogen or C 1-6 alkyl;
R 20 is hydrogen or C 1-6 alkyl;
W is O, S(O) d , CH 2 or NR 9 ;
Group Z is C 2-6 alkenyl, C 2-6 alkynyl, halogen, —CF 3 , —OCF 3 , hydroxy, oxo, —CN, aryl, heteroaryl, C 3-10 cycloalkyl, hetercycloalkyl, —S(O) a R 12 , —S(O) 2 NR 9 R 10 , —C(O)R 9 R 10 , and —NR 9 R 10 ;
Group V is halogen, —NR 13 R 14 , —OCF 3 , —OR 9 , oxo, trifluoromethyl, —CN, C 3-10 cycloalkyl, aryl optionally substituted with X and Y, and het optionally substituted with X and Y;
het for each occurrence is a heterocyclic ring D selected from the group consisting of 4-, 5-, 6-, 7- and 8-membered partially and fully saturated, and unsaturated, heterocyclic rings containing from one to four heteroatoms independently selected from the group consisting of N, O and S, and including any bicyclic group in which said heterocyclic ring D is fused to a benzene ring or a heterocyclic ring E selected from the group consisting of 4-, 5-, 6-, 7- and 8-membered partially and fully saturated, and unsaturated, heterocyclic rings containing from one to four heteroatoms independently selected from the group consisting of N, O and S;
X and Y for each occurrence are independently (A) hydrogen, (B) halogen, (C) trifluoromethyl, (D) —OCF 3 , (E) —CN, (F) C 1-6 alkyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, —OCF 3 , —CF 3 and phenyl, (G) C 1-6 alkoxy, (H) aryl optionally substituted with one or more substituents independently selected from the group consisting of halogen, —OCF 3 , —CF 3 , C 1-4 alkyl and C 1-4 alkoxy, (I) —C(O) 2 R 13 , (J) —C(O)NR 13 R 14 , (K) —C(O)R 13 , (L) —NR 13 C(O)NR 13 R 14 and (M) —NR 13 C(O)R 14 ;
or X and Y for any occurrence in the same variable may be taken together to form (a) a carbocyclic ring D of the formula —(CH 2 ) e — or (b) a heterocyclic ring F selected from the group consisting of —O(CH 2 ) f O—, (CH 2 ) g NH— and —CH═CHNH—;
a and d are each independently 0, 1 or 2;
b is 3, 4, 5, 6 or 7;
c, f, g, j and k are each independently 2, 3, 4, 5 or 6; and
e is 3, 4, 5, 6 or 7.
2 . A compound or pharmaceutically acceptable salt as defined in claim 1 wherein W is oxygen.
3 . A compound or pharmaceutically acceptable salt as defined in claim 2 wherein R 1 is located at the 3 position, R 2 is located at the 5 position, R 3 is located at the 2′ position, R 4 is located at the 3′ position, R 5 is located at the 4′ position, and R 6 is located at the 5′ position.
4 . A compound or pharmaceutically acceptable salt as defined in claim 3 wherein R 3 is hydrogen, or R 3 and R 4 are taken together to form a carbocyclic ring A of the formula —(CH 2 ) b — or a heterocyclic ring A selected from the group consisting of —Q—(CH 2 ) c and —(CH 2 ) j —Q—(CH 2 ) k — wherein Q is O, S or NR 17 , wherein said carbocyclic ring A and said heterocyclic ring A are each independently optionally substituted with one or more substituents independently selected from C 1-4 alkyl, halide or oxo, R 5 is hydroxy, R 6 is hydrogen and R 7 is hydrogen.
5 . A compound or pharmaceutically acceptable salt as defined in claim 4 wherein R 1 and R 2 are each independently methyl, bromo or chloro, and R 8 is hydroxy, methoxy, ethoxy, isopropoxy, NH 2 or NH(CH 3 ).
6 . A compound or pharmaceutically acceptable salt as defined in claim 5 wherein R 4 is S(O) 2 NR 9 R 10 , and R 10 is hydrogen or methyl.
7 . A compound or pharmaceutically acceptable salt as defined in claim 6 wherein R 1 is chloro, R 2 is methyl, R 8 is ethoxy, R 9 is ethyl and R 10 is hydrogen.
8 . A compound or pharmaceutically acceptable salt as defined in claim 6 wherein R 1 is chloro, R 2 is methyl, R 8 is hydroxy, R 9 is ethyl and R 10 is hydrogen.
9 . A compound or pharmaceutically acceptable salt as defined in claim 6 wherein R 1 is chloro, R 2 is methyl, R 8 is ethoxy, R 9 is n-butyl and R 10 is hydrogen.
10 . A compound or pharmaceutically acceptable salt as defined in claim 6 wherein R 1 is chloro, R 2 is methyl, R 8 is hydroxy, R 9 is n-butyl and R 10 is hydrogen.
11 . A compound or pharmaceutically acceptable salt as defined in claim 6 wherein R 1 is chloro, R 2 is methyl, R 8 is ethoxy, R 9 is —CH 2 -cyclopropyl and R 10 is hydrogen.
12 . A compound or pharmaceutically acceptable salt as defined in claim 6 wherein R 1 is chloro, R 2 is methyl, R 8 is hydroxy, R 9 is —CH 2 -cyclopropyl and R 10 is hydrogen.
13 . A compound or pharmaceutically acceptable salt as defined in claim 6 wherein R 1 is chloro, R 2 is methyl, R 8 is isopropoxy, R 9 is cyclopropyl and R 10 is hydrogen.
14 . A compound or pharmaceutically acceptable salt as defined in claim 6 wherein R 1 is chloro, R 2 is methyl, R 8 is hydroxy, R 9 is cyclopropyl and R 10 is hydrogen.
15 . A compound or pharmaceutically acceptable salt as defined in claim 5 wherein R 4 is S(O) 2 NR 9 R 10 , and R 9 and R 10 are taken together with the nitrogen atom to which they are attached to form N(CH 2 ) 4 , N(CH 2 ) 5 , morpholine or
16 . A compound or pharmaceutically acceptable salt as defined in claim 15 wherein R 9 and R 10 are taken together with the nitrogen atom to which they are attached to form N(CH 2 ) 4 .
17 . A compound or pharmaceutically acceptable salt as defined in claim 15 wherein R 9 and R 10 are taken together with the nitrogen atom to which they are attached to form
18 . A compound or pharmaceutically acceptable salt as defined in claim 6 wherein R 9 is hydrogen, isopropyl, —CH 2 -2-thienyl, —CH 2 -cyclopropyl, cyclopropyl, —(CH 2 ) 2 OH, exo-2-norbornyl, methyl, ethyl, 4-fluorophenyl, cyclobutyl, cyclopentyl, cyclohexyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-octyl or n-decyl.
19 . A compound or pharmaceutically acceptable salt as defined in claim 18 wherein R 1 is chloro, R 2 is methyl, R 8 is hydroxy, R 9 is cyclopropyl and R 10 is hydrogen.
20 . A compound or pharmaceutically acceptable salt as defined in claim 18 wherein R 1 is chloro, R 2 is methyl, R 8 is ethoxy, R 9 is cyclopropyl and R 10 is hydrogen.
21 . A compound or pharmaceutically acceptable salt as defined in claim 18 wherein R 1 is methyl, R 2 is methyl, R 8 is hydroxy, R 9 is cyclopropyl and R 10 is methyl.
22 . A compound or pharmaceutically acceptable salt as defined in claim 18 wherein R 1 is methyl, R 2 is methyl, R 8 is ethoxy, R 9 is cyclopropyl and R 10 is methyl.
23 . A compound or pharmaceutically acceptable salt as defined in claim 18 wherein R 1 is methyl, R 2 is methyl, R 8 is hydroxy, R 9 is cyclobutyl and R 10 is methyl.
24 . A compound or pharmaceutically acceptable salt as defined in claim 18 wherein R 1 is methyl, R 2 is methyl, R 8 is ethoxy, R 9 is cyclobutyl and R 10 is methyl.
25 . A compound or pharmaceutically acceptable salt as defined in claim 18 wherein R 1 is methyl, R 2 is methyl, R 8 is hydroxy, R 9 is cyclopropyl and R 10 is hydrogen.
26 . A compound or pharmaceutically acceptable salt as defined in claim 18 wherein R 1 is methyl, R 2 is methyl, R 8 is ethoxy, R 9 is cyclopropyl and R 10 is hydrogen.
27 . A compound or pharmaceutically acceptable salt as defined in claim 18 wherein R 1 is methyl, R 2 is methyl, R 8 is hydroxy, R 9 is cyclobutyl and R 10 is hydrogen.
28 . A compound or pharmaceutically acceptable salt as defined in claim 18 wherein R 1 is methyl, R 2 is methyl, R 8 is ethoxy, R 9 is cyclobutyl and R 10 is hydrogen.
29 . A compound or pharmaceutically acceptable salt as defined in claim 5 wherein R 4 is —C(O)NR 9 R 10 , and R 10 is hydrogen, methyl or ethyl.
30 . A compound or pharmaceutically acceptable salt as defined in claim 29 wherein R 9 is methyl, ethyl, isopropyl, n-propyl, isobutyl, n-butyl, n-pentyl, n-hexyl, 4-fluorophenyl, —CH 2 -2-thienyl, cyclopropyl, —CH 2 -cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, —CH 2 -cyclohexyl, endo-2-norbornyl, exo-2-norbornyl, (S)-1-phenylethyl, (R)-1-phenylethyl, —CH 2 -2-chlorophenyl, —CH 2 -4-chlorophenyl, —CH 2 -4-fluorophenyl, —CH 2 -3-chloro-4-fluorophenyl, —CH 2 -2-chloro-4-fluorophenyl, —CH 2 -2-fluoro-4-chlorophenyl, —CH 2 -3,4-difluorophenyl, —CH 2 -4-isopropylphenyl, —CH 2 -2,3-dichlorophenyl, —CH 2 -2,4-dichlorophenyl, —CH 2 -3,4-dichlorophenyl, —CH 2 -3-trifluoromethyl-4-chlorophenyl, 4-phenylphenyl, 3-(2,4-dimethyl)pentyl, (R)-1-(1-naphthyl)ethyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, (R)-1-(2-naphthyl)ethyl, (R)-2-(1-naphthyl)ethyl, —CH 2 -(1-naphthyl), (R)-1-cyclohexylethyl, (S)-1-cyclohexylethyl, —CH 2 -3,4-methylenedioxyphenyl, —CH 2 -4-t-butylphenyl, —CH 2 -2,3-dichlorophenyl, 1-indanyl, (R)-1-indanyl, (S)-1-indanyl, 5-indanyl, 1-(1,2,3,4-tetrahydronaphthyl) or (R)-1-cyclohexylethyl.
31 . A compound or pharmaceutically acceptable salt as defined in claim 30 wherein R 1 is chloro, R 2 is chloro, R 8 is ethoxy, R 9 is 3-(2,4-dimethyl)pentyl and R 10 is hydrogen.
32 . A compound or pharmaceutically acceptable salt as defined in claim 30 wherein R 1 is chloro, R 2 is chloro, R 8 is hydroxy, R 9 is 3-(2,4-dimethyl)pentyl and R 10 is hydrogen.
33 . A compound or pharmaceutically acceptable salt as defined in claim 30 wherein R 1 is methyl, R 2 is methyl, R 8 is hydroxy, R 9 is cyclopropyl and R 10 is methyl.
34 . A compound or pharmaceutically acceptable salt as defined in claim 30 wherein R 1 is methyl, R 2 is methyl, R 8 is ethoxy, R 9 is cyclopropyl and R 10 is methyl.
35 . A compound or pharmaceutically acceptable salt as defined in claim 30 wherein R 1 is methyl, R 2 is methyl, R 8 is hydroxy, R 9 is cyclobutyl and R 10 is methyl.
36 . A compound or pharmaceutically acceptable salt as defined in claim 30 wherein R 1 is methyl, R 2 is methyl, R 8 is ethoxy, R 9 is cyclobutyl and R 10 is methyl.
37 . A compound or pharmaceutically acceptable salt as defined in claim 30 wherein R 1 is methyl, R 2 is methyl, R 8 is hydroxy, R 9 is 3-(2,4-dimethyl)pentyl and R 10 is hydrogen.
38 . A compound or pharmaceutically acceptable salt as defined in claim 30 wherein R 1 is methyl, R 2 is methyl, R 8 is ethoxy, R 9 is 3-(2,4-dimethyl)pentyl and R 10 is hydrogen.
39 . A compound or pharmaceutically acceptable salt as defined in claim 30 wherein R 1 is methyl, R 2 is methyl, R 8 is hydroxy, R 9 is n-pentyl and R 10 is methyl.
40 . A compound or pharmaceutically acceptable salt as defined in claim 30 wherein R 1 is methyl, R 2 is methyl, R 8 is ethoxy, R 9 is n-pentyl and R 10 is methyl.
41 . A compound or pharmaceutically acceptable salt as defined in claim 30 wherein R 1 is methyl, R 2 is methyl, R 8 is hydroxy, R 9 is isopropyl and R 10 is methyl.
42 . A compound or pharmaceutically acceptable salt as defined in claim 30 wherein R 1 is methyl, R 2 is methyl, R 8 is ethoxy, R 9 is isopropyl and R 10 is methyl.
43 . A compound or pharmaceutically acceptable salt as defined in claim 30 wherein R 1 is methyl, R 2 is methyl, R 8 is hydroxy, R 9 is cyclobutyl and R 10 is methyl.
44 . A compound or pharmaceutically acceptable salt as defined in claim 30 wherein R 1 is methyl, R 2 is methyl, R 8 is ethoxy, R 9 is cyclobutyl and R 10 is methyl.
45 . A compound or pharmaceutically acceptable salt as defined in claim 30 wherein R 1 is methyl, R 2 is methyl, R 8 is NH 2 , R 9 is cyclobutyl and R 10 is methyl.
46 . A compound or pharmaceutically acceptable salt as defined in claim 30 wherein R 1 is chloro, R 2 is chloro, R 8 is hydroxy, R 9 is cyclobutyl and R 10 is methyl.
47 . A compound or pharmaceutically acceptable salt as defined in claim 30 wherein R 1 is chloro, R 2 is chloro, R 8 is ethoxy, R 9 is cyclobutyl and R 10 is methyl.
48 . A compound or pharmaceutically acceptable salt as defined in claim 1 wherein R 4 is —C(O)NR 9 R 10 , and R 9 and R 10 are taken together with the nitrogen atom to which they are attached to form N(CH 2 ) 7 , N(CH 2 ) 6 , N(CH 2 ) 5 , N(CH 2 ) 4 , morpholine,
49 . A compound or pharmaceutically acceptable salt as defined in claim 5 wherein R 4 is —CH 2 NR 9 R 10 , and R 10 is hydrogen, methyl or —COCH 3 .
50 . A compound or pharmaceutically acceptable salt as defined in claim 49 wherein R 9 is methyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, exo-2-norbornyl, —CH 2 -4-fluorophenyl, —CH 2 -4-chlorophenyl, —CH 2 -4-isopropylphenyl, —CH 2 -3,4-methylenedioxyphenyl, (R)-1-(1-naphthyl)ethyl, (R)-1-phenylethyl, (S)-1-phenylethyl, (R)-1-cyclohexylethyl, 1-(1,2,3,4-tetrahydronaphthyl), 1-indanyl or —CH 2 -(1-naphthyl).
51 . A compound or pharmaceutically acceptable salt as defined in claim 5 wherein R 4 is —CH 2 NR 9 R 10 wherein R 9 and R 10 are taken together with the nitrogen atom to which they are attached to form N(CH 2 ) 6 , morpholine,
52 . A compound or pharmaceutically acceptable salt as defined in claim 5 wherein R 4 is —NHCOR 9 .
53 . A compound or pharmaceutically acceptable salt as defined in claim 52 wherein R 9 is cyclopropyl or cyclobutyl.
54 . A compound or pharmaceutically acceptable salt as defined in claim 5 wherein R 4 is —S(O) 2 R 12 .
55 . A compound or pharmaceutically acceptable salt as defined in claim 54 wherein R 12 is 4-chlorophenyl, phenyl, 1-naphthyl, 2-naphthyl, CH 2 -cyclopropyl, isopropyl, CH 2 -cyclobutyl, CH 2 -cyclohexyl, cyclopentyl, CH 2 -4-fluorophenyl, 4-tolyl, methyl, ethyl, n-butyl, CH 2 -phenyl or n-propyl.
56 . A compound or pharmaceutically acceptable salt as defined in claim 55 wherein R 1 is chloro, R 2 is chloro, R 8 is hydroxy and R 12 is ethyl.
57 . A compound or pharmaceutically acceptable salt as defined in claim 55 wherein R 1 is chloro, R 2 is chloro, R 8 is ethoxy and R 12 is ethyl.
58 . A compound or pharmaceutically acceptable salt as defined in claim 55 wherein R 1 is chloro, R 2 is chloro, R 8 is hydroxy and R 12 is —CH 2 -cyclobutyl.
59 . A compound or pharmaceutically acceptable salt as defined in claim 55 wherein R 1 is chloro, R 2 is chloro, R 8 is hydroxy and R 12 is —CH 2 -cyclobutyl.
60 . A compound or pharmaceutically acceptable salt as defined in claim 55 wherein R 1 is chloro, R 2 is chloro, R 8 is hydroxy and R 12 is —CH 2 -cyclohexyl.
61 . A compound or pharmaceutically acceptable salt as defined in claim 55 wherein R 1 is chloro, R 2 is chloro, R 8 is ethoxy and R 12 is —CH 2 -cyclohexyl.
62 . A compound or pharmaceutically acceptable salt as defined in claim 55 wherein R 1 is chloro, R 2 is chloro, R 8 is hydroxy and R 12 is cyclopentyl.
63 . A compound or pharmaceutically acceptable salt as defined in claim 55 wherein R 1 is chloro, R 2 is chloro, R 8 is ethoxy and R 12 is cyclopentyl.
64 . A compound or pharmaceutically acceptable salt as defined in claim 55 wherein R 1 is chloro, R 2 is chloro, R 8 is hydroxy, and R 12 is —CH 2 -cyclopropyl.
65 . A compound or pharmaceutically acceptable salt as defined in claim 55 wherein R 1 is chloro, R 2 is chloro, R 8 is ethoxy, and R 12 is —CH 2 -cyclopropyl.
66 . A compound or pharmaceutically acceptable salt as defined in claim 55 wherein R 1 is chloro, R 2 is chloro, R 8 is hydroxy, and R 12 is —CH 2 -cyclobutyl.
67 . A compound or pharmaceutically acceptable salt as defined in claim 55 wherein R 1 is chloro, R 2 is chloro, R 8 is ethoxy, and R 12 is —CH 2 -cyclobutyl.
68 . A compound or pharmaceutically acceptable salt as defined in claim 55 wherein R 1 is methyl, R 2 is methyl, R 8 is hydroxy, and R 12 is —CH 2 -cyclopropyl.
69 . A compound or pharmaceutically acceptable salt as defined in claim 55 wherein R 1 is methyl, R 2 is methyl, R 8 is ethoxy, and R 12 is —CH 2 -cyclopropyl.
70 . A compound or pharmaceutically acceptable salt as defined in claim 3 wherein R 1 and R 2 are each independently methyl, bromo or chloro, R 3 is hydrogen, R 4 and R 5 are taken together to form
R 6 is hydrogen, R 7 is hydrogen, R 8 is ethoxy, hydroxy or NH 2 , and R 10 is hydrogen or methyl.
71 . A compound or pharmaceutically acceptable salt as defined in claim 5 wherein R 3 is hydrogen, and R 4 is —OR 11 .
72 . A compound or pharmaceutically acceptable salt as defined in claim 71 wherein R 11 is phenyl, 4-chlorophenyl or 4-fluorophenyl.
73 . A compound or pharmaceutically acceptable salt as defined in claim 5 wherein R 3 is hydrogen, and R 4 is —(C 1-6 alkyl)-OR 11 .
74 . A compound or pharmaceutically acceptable salt as defined in claim 73 wherein R 4 is —CH 2 —OR 11 .
75 . A compound or pharmaceutically acceptable salt as defined in claim 74 wherein R 11 is phenyl or 4-fluorophenyl.
76 . A compound or pharmaceutically acceptable salt as defined in claim 5 wherein R 3 and R 4 are taken together to form said carbocyclic ring A or said heterocyclic ring A.
77 . A compound or pharmaceutically acceptable salt as defined in claim 76 wherein R 3 and R 4 are taken together to form said carbocyclic ring A.
78 . A compound or pharmaceutically acceptable group as defined in claim 77 wherein R 3 and R 4 are taken together to form —(CH 2 ) 3 —, —CH 2 —C(CH 3 ) 2 —CH 2 —or —(CH 2 ) 4 —.
79 . A compound or pharmaceutically acceptable salt as defined in claim 78 wherein R 1 is methyl, R 2 is methyl, R 8 is hydroxy, and R 3 and R 4 are taken together to form —(CH 2 ) 3 —.
80 . A compound or pharmaceutically acceptable salt as defined in claim 78 wherein R 1 is methyl, R 2 is methyl, R 8 is ethoxy, and R 3 and R 4 are taken together to form —(CH 2 ) 3 —.
81 . A compound or pharmaceutically acceptable salt as defined in claim 78 wherein R 1 is chloro, R 2 is methyl, R 8 is hydroxy, and R 3 and R 4 are taken together to form —(CH 2 ) 3 —.
82 . A compound or pharmaceutically acceptable salt as defined in claim 78 wherein R 1 is chloro, R 2 is methyl, R 8 is ethoxy, and R 3 and R 4 are taken together to form —(CH 2 ) 3 —.
83 . A compound or pharmaceutically acceptable salt as defined in claim 78 wherein R 1 is methyl, R 2 is methyl, R 8 is hydroxy, and R 3 and R 4 are taken together to form —(CH 2 ) 4 —.
84 . A compound or pharmaceutically acceptable salt as defined in claim 78 wherein R 1 is methyl, R 2 is methyl, R 8 is ethoxy, and R 3 and R 4 are taken together to form —(CH 2 ) 4 —.
85 . A compound or pharmaceutically acceptable salt as defined in claim 76 wherein R 3 and R 4 are taken together to form said heterocyclic ring A.
86 . A compound or pharmaceutically acceptable salt as defined in claim 85 wherein said heterocyclic ring A is —Q—(CH 2 ) c —.
87 . A compound or pharmaceutically acceptable salt as defined in claim 1 wherein R 8 is —OR 9 .
88 . A compound or pharmaceutically acceptable salt as defined in claim 87 wherein R 9 is C 1-12 alkyl.
89 . A compound or pharmaceutically acceptable salt as defined in claim 88 wherein R 9 is methyl.
90 . A compound or pharmaceutically acceptable salt as defined in claim 88 wherein R 9 is ethyl.
91 . A compound or pharmaceutically acceptable salt as defined in claim 88 wherein R 9 is isopropyl.
92 . A pharmaceutically acceptable salt as defined in claim 1 wherein said salt is a potassium salt.
93 . A pharmaceutically acceptable salt as defined in claim 1 wherein said salt is a sodium salt.
94 . A compound as defined in claim 1 selected from the group consisting of:
N-[3-chloro-4-(3-cyclopropylsulfamoyl-4-hydroxy-phenoxy)-5-methyl-phenyl]-oxamic acid,
N-[4-(3-cyclopropylsulfamoyl-4-hydroxy-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid,
N-{4-[3-(cyclobutyl-methyl-carbamoyl)-4-hydroxy-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid,
N-{3-chloro-4-[3-(cyclobutyl-methyl-carbamoyl)-4-hydroxy-phenoxy]-5-methyl-phenyl}-oxamic acid,
N-[4-(7-hydroxy-indan-4-yloxy)-3,5-dimethyl-phenyl]-oxamic acid,
N-{3,5-dichloro-4-[3-(cyclobutyl-methyl-carbamoyl)-4-hydroxy-phenoxy]-phenyl}-oxamic acid,
N-[3,5-dichloro-4-(3-cyclopentanesulfonyl-4-hydroxy-phenoxy)-phenyl]-oxamic acid,
N-[3,5-dichloro-4-(3-cyclopropylmethanesulfonyl-4-hydroxy-phenoxy)-phenyl]-oxamic acid,
N-[3,5-dichloro-4-(3-cyclobutylmethanesulfonyl-4-hydroxy-phenoxy)-phenyl]-oxamic acid,
N-[4-(3-cyclopropylmethanesulfonyl-4-hydroxy-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid,
N-[3-chloro-4-(3-cyclobutylmethanesulfonyl-4-hydroxy-phenoxy)-5-methyl-phenyl]-oxamic acid,
N-[4-(3-cyclobutylmethanesulfonyl-4-hydroxy-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid,
N-[4-(3-cyclopentylmethanesulfonyl-4-hydroxy-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid,
N-[3-chloro-4-(3-cyclopentylmethanesulfonyl-4-hydroxy-phenoxy)-5-methyl-phenyl]-oxamic acid,
N-[3,5-dichloro-4-(3-cyclopentylmethanesulfonyl-4-hydroxy-phenoxy)-phenyl]-oxamic acid,
N-[4-(3-cyclohexylmethanesulfonyl-4-hydroxy-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid,
N-[3-chloro-4-(3-cyclohexylmethanesulfonyl-4-hydroxy-phenoxy)-5-methyl-phenyl]-oxamic acid,
N-[3,5-dichloro-4-(3-cyclohexylmethanesulfonyl-4-hydroxy-phenoxy)-phenyl]-oxamic acid,
N-[3,5-dichloro-4-[3-(4-fluoro-benzenesulfonyl)-4-hydroxy-phenoxy)-phenyl]-oxamic acid,
N-{4-[3-(4-fluoro-benzenesulfonyl)-4-hydroxy-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid and
N-{3-chloro-4-[3-(4-fluoro-benzenesulfonyl)-4-hydroxy-phenoxy]-5-methyl-phenyl}-oxamic acid.
95 . A pharmaceutically acceptable salt of each of said compounds as defined in claim 94 wherein said salt is a potassium salt.
96 . A pharmaceutically acceptable salt of each of said compounds as defined in claim 94 wherein said salt is a sodium salt.
97 . A compound as defined in claim 1 selected from the group consisting of
N-[3-chloro-4-(3-cyclopropylsulfamoyl-4-hydroxy-phenoxy)-5-methyl-phenyl]-oxamic acid methyl ester,
N-[4-(3-cyclopropylsulfamoyl-4-hydroxy-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid methyl ester,
N-{4-[3-(cyclobutyl-methyl-carbamoyl)-4-hydroxy-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid methyl ester,
N-{3-chloro-4-[3-(cyclobutyl-methyl-carbamoyl)-4-hydroxy-phenoxy]-5-methyl-phenyl}-oxamic acid methyl ester,
N-[4-(7-hydroxy-indan-4-yloxy)-3,5-dimethyl-phenyl]-oxamic acid methyl ester,
N-{3,5-dichloro-4-[3-(cyclobutyl-methyl-carbamoyl)-4-hydroxy-phenoxy]-phenyl}-oxamic acid methyl ester,
N-[3,5-dichloro-4-(3-cyclopentanesulfonyl-4-hydroxy-phenoxy)-phenyl]-oxamic acid methyl ester,
N-[3,5-dichloro-4-(3-cyclopropylmethanesulfonyl-4-hydroxy-phenoxy)-phenyl]-oxamic acid methyl ester,
N-[3,5-dichloro-4-(3-cyclobutylmethanesulfonyl-4-hydroxy-phenoxy)-phenyl]-oxamic acid methyl ester,
N-[4-(3-cyclopropylmethanesulfonyl-4-hydroxy-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid methyl ester,
N-[3-chloro-4-(3-cyclobutylmethanesulfonyl-4-hydroxy-phenoxy)-5-methyl-phenyl]-oxamic acid methyl ester,
N-[4-(3-cyclobutylmethanesulfonyl-4-hydroxy-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid methyl ester,
N-[4-(3-cyclopentylmethanesulfonyl-4-hydroxy-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid methyl ester,
N-[3-chloro-4-(3-cyclopentylmethanesulfonyl-4-hydroxy-phenoxy)-5-methyl-phenyl]-oxamic acid methyl ester,
N-[3,5-dichloro-4-(3-cyclopentylmethanesulfonyl-4-hydroxy-phenoxy)-phenyl]-oxamic acid methyl ester,
N-[4-(3-cyclohexylmethanesulfonyl-4-hydroxy-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid methyl ester,
N-[3-chloro-4-(3-cyclohexylmethanesulfonyl-4-hydroxy-phenoxy)-5-methyl-phenyl]-oxamic acid methyl ester,
N-[3,5-dichloro-4-(3-cyclohexylmethanesulfonyl-4-hydroxy-phenoxy)-phenyl]-oxamic acid methyl ester,
N-[3,5-dichloro-4-[3-(4-fluoro-benzenesulfonyl)-4-hydroxy-phenoxy)-phenyl]-oxamic acid methyl ester,
N-{4-[3-(4-fluoro-benzenesulfonyl)-4-hydroxy-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid methyl ester and
N-{3-chloro-4-[3-(4-fluoro-benzenesulfonyl)-4-hydroxy-phenoxy]-5-methyl-phenyl}-oxamic acid methyl ester.
98 . A compound as defined in claim 1 selected from the group consisting of
N-[3-chloro-4-(3-cyclopropylsulfamoyl-4-hydroxy-phenoxy)-5-methyl-phenyl]-oxamic acid ethyl ester,
N-[4-(3-cyclopropylsulfamoyl-4-hydroxy-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid ethyl ester,
N-{4-[3-(cyclobutyl-methyl-carbamoyl)-4-hydroxy-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid ethyl ester,
N-{3-chloro-4-[3-(cyclobutyl-methyl-carbamoyl)-4-hydroxy-phenoxy]-5-methyl-phenyl}-oxamic acid ethyl ester,
N-[4-(7-hydroxy-indan-4-yloxy)-3,5-dimethyl-phenyl]-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[3-(cyclobutyl-methyl-carbamoyl)-4-hydroxy-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-[3,5-dichloro-4-(3-cyclopentanesulfonyl-4-hydroxy-phenoxy)-phenyl]-oxamic acid ethyl ester,
N-[3,5-dichloro-4-(3-cyclopropylmethanesulfonyl-4-hydroxy-phenoxy)-phenyl]-oxamic acid ethyl ester,
N-[3,5-dichloro-4-(3-cyclobutylmethanesulfonyl-4-hydroxy-phenoxy)-phenyl]-oxamic acid ethyl ester,
N-[4-(3-cyclopropylmethanesulfonyl-4-hydroxy-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid ethyl ester,
N-[3-chloro-4-(3-cyclobutylmethanesulfonyl-4-hydroxy-phenoxy)-5-methyl-phenyl]-oxamic acid ethyl ester,
N-[4-(3-cyclobutylmethanesulfonyl-4-hydroxy-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid ethyl ester,
N-[4-(3-cyclopentylmethanesulfonyl-4-hydroxy-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid ethyl ester,
N-[3-chloro-4-(3-cyclopentylmethanesulfonyl-4-hydroxy-phenoxy)-5-methyl-phenyl]-oxamic acid ethyl ester,
N-[3,5-dichloro-4-(3-cyclopentylmethanesulfonyl-4-hydroxy-phenoxy)-phenyl]-oxamic acid ethyl ester,
N-[4-(3-cyclohexylmethanesulfonyl-4-hydroxy-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid ethyl ester,
N-[3-chloro-4-(3-cyclohexylmethanesulfonyl-4-hydroxy-phenoxy)-5-methyl-phenyl]-oxamic acid ethyl ester,
N-[3,5-dichloro-4-(3-cyclohexylmethanesulfonyl-4-hydroxy-phenoxy)-phenyl]-oxamic acid ethyl ester,
N-[3,5-dichloro-4-[3-(4-fluoro-benzenesulfonyl)-4-hydroxy-phenoxy)-phenyl]-oxamic acid ethyl ester,
N-{4-[3-(4-fluoro-benzenesulfonyl)-4-hyd roxy-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid ethyl ester and
N-{3-chloro-4-[3-(4-fluoro-benzenesulfonyl)-4-hydroxy-phenoxy]-5-methyl-phenyl}-oxamic acid ethyl ester.
99 . A compound as defined in claim 1 selected from the group consisting of
N-[3-chloro-4-(3-cyclopropylsulfamoyl-4-hydroxy-phenoxy)-5-methyl-phenyl]-oxamic acid isopropyl ester,
N-[4-(3-cyclopropylsulfamoyl-4-hydroxy-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid isopropyl ester,
N-{4-[3-(cyclobutyl-methyl-carbamoyl)-4-hydroxy-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid isopropyl ester,
N-{3-chloro-4-[3-(cyclobutyl-methyl-carbamoyl)-4-hydroxy-phenoxy]-5-methyl-phenyl}-oxamic acid isopropyl ester,
N-[4-(7-hydroxy-indan-4-yloxy)-3,5-dimethyl-phenyl]-oxamic acid isopropyl ester,
N-{3,5-dichloro-4-[3-(cyclobutyl-methyl-carbamoyl)-4-hydroxy-phenoxy]-phenyl}-oxamic acid isopropyl ester,
N-[3,5-dichloro-4-(3-cyclopentanesulfonyl-4-hydroxy-phenoxy)-phenyl]-oxamic acid isopropyl ester,
N-[3,5-dichloro-4-(3-cyclopropylmethanesulfonyl-4-hydroxy-phenoxy)-phenyl]-oxamic acid isopropyl ester,
N-[3,5-dichloro-4-(3-cyclobutylmethanesulfonyl-4-hydroxy-phenoxy)-phenyl]-oxamic acid isopropyl ester,
N-[4-(3-cyclopropylmethanesulfonyl-4-hydroxy-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid isopropyl ester,
N-[3-chloro-4-(3-cyclobutylmethanesulfonyl-4-hydroxy-phenoxy)-5-methyl-phenyl]-oxamic acid isopropyl ester,
N-[4-(3-cyclobutylmethanesulfonyl-4-hydroxy-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid isopropyl ester,
N-[4-(3-cyclopentylmethanesulfonyl-4-hydroxy-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid isopropyl ester,
N-[3-chloro-4-(3-cyclopentylmethanesulfonyl-4-hydroxy-phenoxy)-5-methyl-phenyl]-oxamic acid isopropyl ester,
N-[3,5-dichloro-4-(3-cyclopentylmethanesulfonyl-4-hydroxy-phenoxy)-phenyl]-oxamic acid isopropyl ester,
N-[4-(3-cyclohexylmethanesulfonyl-4-hydroxy-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid isopropyl ester,
N-[3-chloro-4-(3-cyclohexylmethanesulfonyl-4-hydroxy-phenoxy)-5-methyl-phenyl]-oxamic acid isopropyl ester,
N-[3,5-dichloro-4-(3-cyclohexylmethanesulfonyl-4-hydroxy-phenoxy)-phenyl]-oxamic acid isopropyl ester,
N-[3,5-dichloro-4-[3-(4-fluoro-benzenesulfonyl)-4-hydroxy-phenoxy)-phenyl]-oxamic acid isopropyl ester,
N-{4-[3-(4-fluoro-benzenesulfonyl)-4-hydroxy-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid isopropyl ester and
N-{3-chloro-4-[3-(4-fluoro-benzenesulfonyl)-4-hydroxy-phenoxy]-5-methyl-phenyl}-oxamic acid isopropyl ester.
100 . A compound as defined in claim 1 selected from the group consisting of
N-{3,5-dichloro-4-[4-hydroxy-3-(pyrrolidine-1-sulfonyl)-phenoxy]-phenyl}-oxamic acid,
N-[4-(3-cyclopropylsulfamoyl-4-hydroxy-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid ethyl ester,
N-[4-(4-hydroxy-3-methylsulfamoyl-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid ethyl ester,
N-{4-[3-(4-fluoro-phenylsulfamoyl)-4-hydroxy-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid ethyl ester,
N-[4-(3-dimethylsulfamoyl-4-hydroxy-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid ethyl ester,
N-{4-[3-(cyclopropyl-methyl-sulfamoyl)-4-hydroxy-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid ethyl ester,
N-{4-[3-(cyclobutyl-methyl-sulfamoyl)-4-hydroxy-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid ethyl ester,
N-[4-(3-cyclobutylsulfamoyl-4-hydroxy-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid ethyl ester,
N-[4-(3-cyclopentylsulfamoyl-4-hydroxy-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid ethyl ester,
N-{4-[4-hydroxy-3-(pyrrolidine-1-sulfonyl)-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid ethyl ester,
N-{4-[4-hydroxy-3-(piperidine-1-sulfonyl)-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid ethyl ester,
N-[4-(3-cyclohexylsulfamoyl-4-hydroxy-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid ethyl ester,
N-[4-(4-hydroxy-3-propylsulfamoyl-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid ethyl ester,
N-[4-(3-butylsulfamoyl-4-hydroxy-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid ethyl ester,
N-{4-[3-(cyclopropyl-methyl-sulfamoyl)-4-hydroxy-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid,
N-{4-[3-(cyclobutyl-methyl-sulfamoyl)-4-hydroxy-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid,
N-[4-(3-cyclopropylsulfamoyl-4-hydroxy-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid,
N-[4-(3-cyclobutylsulfamoyl-4-hydroxy-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid,
N-[3-chloro-4-(3-cyclopropylsulfamoyl-4-hydroxy-phenoxy)-5-methyl-phenyl]-oxamic acid ethyl ester,
N-[3-chloro-4-(3-cyclobutylsulfamoyl-4-hydroxy-phenoxy)-5-methyl-phenyl]-oxamic acid ethyl ester,
N-[3-chloro-4-(3-cyclopentylsulfamoyl-4-hydroxy-phenoxy)-5-methyl-phenyl]-oxamic acid ethyl ester,
N-[3-chloro-4-(3-cyclohexylsulfamoyl-4-hydroxy-phenoxy)-5-methyl-phenyl]-oxamic acid ethyl ester,
N-[3-chloro-4-(4-hydroxy-3-sulfamoyl-phenoxy)-5-methyl-phenyl]-oxamic acid ethyl ester,
N-{3-chloro-4-[4-hydroxy-3-(piperidine-1-sulfonyl)-phenoxy]-5-methyl-phenyl}-oxamic acid ethyl ester,
N-{3-chloro-4-[3-(4-fluoro-phenylsulfamoyl)-4-hydroxy-phenoxy]-5-methyl-phenyl}-oxamic acid ethyl ester,
N-[3-chloro-4-(3-dimethysulfamoyl-4-hydroxy-phenoxy)-5-methyl-phenyl]-oxamic acid ethyl ester,
N-[3-chloro-4-(4-hydroxy-3-methylsulfamoyl-phenoxy)-5-methyl-phenyl]-oxamic acid ethyl ester,
N-[3-chloro-4-(4-hydroxy-3-propylsulfamoyl-phenoxy)-5-methyl-phenyl]-oxamic acid ethyl ester,
N-[3-chloro-4-(4-hydroxy-3-pentylsulfamoyl-phenoxy)-5-methyl-phenyl]-oxamic acid ethyl ester,
N-[3-chloro-4-(3-hexylsulfamoyl-4-hydroxy-phenoxy)-5-methyl-phenyl]-oxamic acid ethyl ester,
N-[3-chloro-4-(4-hydroxy-3-octylsulfamoyl-phenoxy)-5-methyl-phenyl]-oxamic acid ethyl ester,
N-[3-chloro-4-(3-decylsulfamoyl-4-hydroxy-phenoxy)-5-methyl-phenyl]-oxamic acid ethyl ester,
N-[4-(3-butylsulfamoyl-4-hydroxy-phenoxy)-3-chloro-5-methyl-phenyl]-oxamic acid ethyl ester,
N-{3-chloro-4-[3-(ethyl-methyl-sulfamoyl)-4-hydroxy-phenoxy]-5-methyl-phenyl}-oxamic acid ethyl ester,
N-{3-chloro-4-[4-hydroxy-3-(methyl-propyl-sulfamoyl)-phenoxy]-5-methyl-phenyl}-oxamic acid ethyl ester,
N-{4-[3-(butyl-methyl-sulfamoyl)-4-hydroxy-phenoxy]-3-chloro-5-methyl-phenyl}-oxamic acid ethyl ester,
N-{3-chloro-4-[4-hydroxy-3-(morpholine-4-sulfonyl)-phenoxy]-5-methyl-phenyl}-oxamic acid ethyl ester,
N-{3-chloro-4-[3-(cyclopropylmethyl-sulfamoyl)-4-hydroxy-phenoxy]-5-methyl-phenyl}-oxamic acid ethyl ester,
N-{3-chloro-4-[4-hydroxy-3-(2-hydroxy-ethylsulfamoyl)-phenoxy]-5-methyl-phenyl}-oxamic acid ethyl ester,
N-[3-chloro-4-(3-cyclopropylsulfamoyl-4-hydroxy-phenoxy)-5-methyl-phenyl]-oxamic acid isopropyl ester,
N-[3-chloro-4-(3-cyclopropylsulfamoyl-4-hydroxy-phenoxy)-5-methyl-phenyl]-oxamic acid,
N-[3-chloro-4-(3-cyclobutylsulfamoyl-4-hydroxy-phenoxy)-5-methyl-phenyl]-oxamic acid,
N-[3-chloro-4-(3-cyclopentylsulfamoyl-4-hydroxy-phenoxy)-5-methyl-phenyl]-oxamic acid,
N-[3-chloro-4-(3-cyclohexylsulfamoyl-4-hydroxy-phenoxy)-5-methyl-phenyl]-oxamic acid,
N-[3-chloro-4-(4-hydroxy-3-sulfamoyl-phenoxy)-5-methyl-phenyl]-oxamic acid,
N-{3-chloro-4-[3-(4-fluoro-phenylsulfamoyl)-4-hydroxy-phenoxy]-5-methyl-phenyl}-oxamic acid,
N-[3-chloro-4-(4-hydroxy-3-propylsulfamoyl-phenoxy)-5-methyl-phenyl]-oxamic acid,
N-[4-(3-butylsulfamoyl-4-hydroxy-phenoxy)-3-chloro-5-methyl-phenyl]-oxamic acid,
N-{3-chloro-4-[4-hydroxy-3-(morpholine-4-sulfonyl)-phenoxy]-5-methyl-phenyl}-oxamic acid,
N-{3,5-dichloro-4-[4-hydroxy-3-(pyrrolidine-1-sulfonyl)-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[3-(3,4-dihydro-1H-isoquinoline-2-sulfonyl)-4-hydroxy-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-[3,5-dichloro-4-(3-cyclobutylsulfamoyl-4-hydroxy-phenoxy)-phenyl]-oxamic acid ethyl ester,
N-{4-[3-(bicyclo[2.2.1]hept-2-ylsulfamoyl)-4-hydroxy-phenoxy]-3,5-dichloro-phenyl}-oxamic acid ethyl ester,
N-(3,5-dichloro-4-{4-hydroxy-3-[(thiophen-2-ylmethyl)-sulfamoyl]-phenoxy}-phenyl)-oxamic acid ethyl ester,
N-[3,5-dichloro-4-(4-hydroxy-3-isopropylsulfamoyl-phenoxy)-phenyl]-oxamic acid ethyl ester,
N-[3,5-dichloro-4-(3-dimethylsulfamoyl-4-hydroxy-phenoxy)-phenyl]-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[4-hydroxy-3-(pyrrolidine-1-sulfonyl)-phenoxy]-phenyl}-oxamic acid and
N-[3,5-dichloro-4-(4-hydroxy-3-isopropylsulfamoyl-phenoxy)-phenyl]-oxamic acid.
101 . A compound as defined in claim 1 selected from the group consisting of
N-{3,5-dichloro-4-[3-(3,3-dimethyl-piperidine-1-carbonyl)-4-hydroxy-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-{4-[3-(3,4-dihydro-1H-isoquinoline-2-carbonyl)-4-hydroxy-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid ethyl ester,
N-{4-[3-(3,4-dihydro-2H-quinoline-1-carbonyl)-4-hydroxy-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid ethyl ester,
N-{4-[3-(2,3-dihydro-indole-1-carbonyl)-4-hydroxy-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid ethyl ester,
N-{4-[3-(3,3-dimethyl-piperidine-1-carbonyl)-4-hydroxy-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid ethyl ester,
N-{4-[4-hydroxy-3-(3-methyl-3-phenyl-piperidine-1-carbonyl)-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid ethyl ester,
N-{4-[3-(azepane-1-carbonyl)-4-hydroxy-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid ethyl ester,
N-{4-[4-hydroxy-3-(1-naphthalen-1-yl-(1R)-ethylcarbamoyl)-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid ethyl ester,
N-{4-[4-hydroxy-3-(1-phenyl-(1R)-ethylcarbamoyl)-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid ethyl ester,
N-{4-[3-(bicyclo[2.2.1]hept-2-ylcarbamoyl)-4-hydroxy-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid ethyl ester,
N-{4-[3-(4-chloro-benzylcarbamoyl)-4-hydroxy-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid ethyl ester,
N-{4-[3-(1-cyclohexyl-(1R)-ethylcarbamoyl)-4-hydroxy-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid ethyl ester,
N-{4-[4-hydroxy-3-(1-naphthalen-2-yl-(1R)-ethylcarbamoyl)-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid ethyl ester,
N-[4-(3-cyclobutylcarbamoyl-4-hydroxy-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid ethyl ester,
N-[4-(3-cyclopentylcarbamoyl-4-hydroxy-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid ethyl ester,
N-{4-[4-hydroxy-3-(1-isopropyl-2-methyl-propylcarbamoyl)-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid ethyl ester,
N-{4-[4-hydroxy-3-(pyrrolidine-1-carbonyl)-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid ethyl ester,
N-{4-[4-hydroxy-3-(morpholine-4-carbonyl)-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid ethyl ester,
N-{4-[4-hydroxy-3-(1-naphthalen-1-yl-(1R)ethylcarbamoyl)-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid,
N-{4-[4-hydroxy-3-(1-phenyl-(1R)ethylcarbamoyl)-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid,
N-{4-[3-(cyclopropyl-methyl-carbamoyl)-4-hydroxy-phenoxy]-3,5-dimethyl-pentyl}-oxamic acid,
N-{4-[3-(cyclobutyl-methyl-carbamoyl)-4-hydroxy-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid,
N-{4-[4-hydroxy-3-(1-isopropyl-2-methyl-propylcarbamoyl)-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid,
N-{4-[3-(cyclopentyl-methyl-carbamoyl)-4-hydroxy-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid,
N-{4-[3-(cyclohexyl-methyl-carbamoyl)-4-hydroxy-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid,
N-{3-chloro-4-[4-hydroxy-3-(3-methyl-3-phenyl-piperidine-1-carbonyl)-phenoxy]-5-methyl-phenyl}-oxamic acid ethyl ester,
N-{4-[3-(azepane-1-carbonyl)-4-hydroxy-phenoxy]-3-chloro-5-methyl-phenyl}-oxamic acid ethyl ester,
N-{3-chloro-4-[3-(3,3-dimethyl-piperidine-1-carbonyl)-4-hydroxy-phenoxy]-5-methyl-phenyl}-oxamic acid ethyl ester,
N-(3-chloro-4-{4-hydroxy-3-[(thiophen-2-ylmethyl)-carbamoyl]-phenoxy}-5-methyl-phenyl)-oxamic acid ethyl ester,
N-{3-chloro-4-[3-(2,3-dichloro-benzylcarbamoyl)-4-hydroxy-phenoxy]-5-methyl-phenyl}-oxamic acid ethyl ester,
N-[3-chloro-4-(3-cyclopropylcarbamoyl-4-hydroxy-phenoxy)-5-methyl-phenyl]-oxamic acid ethyl ester,
N-{3-chloro-4-[3-(2,3-dihydro-indole-1-carbonyl)-4-hydroxy-phenoxy]-methyl-phenyl}-oxamic acid ethyl ester,
N-{3-chloro-4-[3-(3,4-dihydro-2H-quinoline-1-carbonyl)-4-hydroxy-phenoxy]-5-methyl-phenyl}-oxamic acid ethyl ester,
N-{3-chloro-4-[3-(3,4-dihydro-1H-isoquinoline-2-carbonyl)-4-hydroxy-phenoxy]-5-methyl-phenyl}-oxamic acid ethyl ester,
N-{3-chloro-4-[4-hydroxy-3-(indan-1-ylcarbamoyl)-phenoxy]-5-methyl-phenyl}-oxamic acid ethyl ester,
N-{3-chloro-4-[4-hydroxy-3-(indan-5-ylcarbamoyl)-phenoxy]-5-methyl-phenyl}-oxamic acid ethyl ester,
N-{4-[3-(bicyclo[2.2.1]hept-2-ylcarbamoyl)-4-hydroxy-phenoxy]-3-chloro-5-methyl-phenyl}-oxamic acid ethyl ester,
N-{3-chloro-4-[3-(cyclohexylmethyl-carbamoyl)-4-hydroxy-phenoxy]-5-methyl-phenyl}-oxamic acid ethyl ester,
N-{3-chloro-4-[3-(1-cyclohexyl-(1R)ethylcarbamoyl)-4-hydroxy-phenoxy]-5-methyl-phenyl}-oxamic acid ethyl ester,
N-{3-chloro-4-[3-(1-cyclohexyl-(1S)ethylcarbamoyl)-4-hydroxy-phenoxy]-5-methyl-phenyl}-oxamic acid ethyl ester,
N-{3-chloro-4-[4-hydroxy-3-(piperidine-1-carbonyl)-phenoxy]-5-methyl-phenyl}-oxamic acid ethyl ester,
N-{4-[3-(azocane-1-carbonyl)-4-hydroxy-phenoxy]-3-chloro-5-methyl-phenyl}-oxamic acid ethyl ester,
N-[3-chloro-4-(3-cyclohexylcarbamoyl-4-hydroxy-phenoxy)-5-methyl-phenyl]-oxamic acid ethyl ester,
N-{3-chloro-4-[4-hydroxy-3-(1-phenyl-(1R)ethylcarbamoyl)-phenoxy]-5-methyl-phenyl}-oxamic acid ethyl ester,
N-[3-chloro-4-(4-hydroxy-3-propylcarbamoyl-phenoxy)-5-methyl-phenyl]-oxamic acid ethyl ester,
N-[4-(3-butylcarbamoyl-4-hydroxy-phenoxy)-3-chloro-5-methyl-phenyl]-oxamic acid ethyl ester,
N-[3-chloro-4-(4-hydroxy-3-pentylcarbamoyl-phenoxy)-5-methyl-phenyl]-oxamic acid ethyl ester,
N-[3-chloro-4-(3-hexylcarbamoyl-4-hydroxy-phenoxy)-5-methyl-phenyl]-oxamic acid ethyl ester,
N-{3-chloro-4-[3-(1,1-dimethyl-propylcarbamoyl)-4-hydroxy-phenoxy]-5-methyl-phenyl}-oxamic acid ethyl ester,
N-[3-chloro-4-(3-diisopropylcarbamoyl-4-hydroxy-phenoxy)-5-methyl-phenyl]-oxamic acid ethyl ester,
N-{3-chloro-4-[3-(2,2-dimethyl-propylcarbamoyl)-4-hydroxy-phenoxy]-5-methyl-phenyl}-oxamic acid ethyl ester,
N-{3-chloro-4-[3-(1,2-dimethyl-propylcarbamoyl)-4-hydroxy-phenoxy]-5-methyl-phenyl}-oxamic acid ethyl ester,
N-{3-chloro-4-[4-hydroxy-3-(1-phenyl-(1S)ethylcarbamoyl)-phenoxy]-5-methyl-phenyl}-oxamic acid ethyl ester,
N-{3-chloro-4-[3-(ethyl-methyl-carbamoyl)-4-hydroxy-phenoxy]-5-methyl-phenyl}-oxamic acid ethyl ester,
N-{3-chloro-4-[4-hydroxy-3-(methyl-propyl-carbamoyl)-phenoxy]-5-methyl-phenyl}-oxamic acid ethyl ester,
N-{3-chloro-4-[3-(ethyl-isopropyl-carbamoyl)-4-hydroxy-phenoxy]-5-methyl-phenyl}-oxamic acid ethyl ester,
N-{3-chloro-4-[3-(cyclobutyl-methyl-carbamoyl)-4-hydroxy-phenoxy]-5-methyl-phenyl}-oxamic acid ethyl ester,
N-{4-[3-(azepane-1-carbonyl)-4-hydroxy-phenoxy]-3-chloro-5-methyl-phenyl}-oxamic acid,
N-{3-chloro-4-[3-(1-cyclohexyl-(1S)ethylcarbamoyl)-4-hydroxy-phenoxy]-5-methyl-phenyl}-oxamic acid,
N-{3-chloro-4-[3-(cyclobutyl-methyl-carbamoyl)-4-hydroxy-phenoxy]-5-methyl-phenyl}-oxamic acid,
N-{4-[3-(bicyclo[2.2.1]hept-2-ylcarbamoyl)-4-hydroxy-phenoxy]-3,5-dichloro-phenyl}-oxamic acid ethyl ester,
N-{4-[3-(bicyclo[2.2.1]hept-2-ylcarbamoyl)-4-hydroxy-phenoxy]-3,5-dichloro-phenyl}-oxamic acid ethyl ester,
N-(3,5-dichloro-4-{4-hydroxy-3-[(thiophen-2-ylmethyl)-carbamoyl]-phenoxy}-phenyl)-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[3-(2-chloro-benzylcarbamoyl)-4-hydroxy-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[4-hydroxy-3-(3-methyl-3-phenyl-piperidine-1-carbonyl)-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[3-(3,4-dihydro-1H-isoquinoline-2-carbonyl)-4-hydroxy-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[4-hydroxy-3-(indan-1-ylcarbamoyl)-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-(4-{3-[(benzo[1,3]dioxol-5-ylmethyl)-carbamoyl]-4-hydroxy-phenoxy}-3,5-dichloro-phenyl)-oxamic acid ethyl ester,
N-{4-[3-(azepane-1-carbonyl)-4-hydroxy-phenoxy]-3,5-dichloro-phenyl}-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[4-hydroxy-3-(4-methyl-piperidine-1-carbonyl)-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[3-(4-fluoro-phenylcarbamoyl)-4-hydroxy-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[3-(cyclohexylmethyl-carbamoyl)-4-hydroxy-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[3-(1-cyclohexyl-(1R)ethylcarbamoyl)-4-hydroxy-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[3-(1-cyclohexyl-(1S)ethylcarbamoyl)-4-hydroxy-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[4-hydroxy-3-(piperidine-1-carbonyl)-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[4-hydroxy-3-(3-methyl-piperidine-1-carbonyl)-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-{4-[3-(biphenyl-3-ylcarbamoyl)-4-hydroxy-phenoxy]-3,5-dichloro-phenyl}-oxamic acid ethyl ester,
N-[3,5-dichloro-4-(3-cyclopropylcarbamoyl-4-hydroxy-phenoxy)-phenyl]-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[3-(2,3-dichloro-benzylcarbamoyl)-4-hydroxy-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-[3,5-dichloro-4-(3-cyclobutylcarbamoyl-4-hydroxy-phenoxy)-phenyl]-oxamic acid ethyl ester,
N-[3,5-dichloro-4-(3-cyclopentylcarbamoyl-4-hydroxy-phenoxy)-phenyl]-oxamic acid ethyl ester,
N-(3,5-dichloro-4-{4-hydroxy-3-[(naphthalen-1-ylmethyl)-carbamoyl]-phenoxy}-phenyl)-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[3-(4-fluoro-benzylcarbamoyl)-4-hydroxy-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-{4-[3-(azocane-1-carbonyl)-4-hydroxy-phenoxy]-3,5-dichloro-phenyl}-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[4-hydroxy-3-(1,2,3,4-tetrahydro-naphthalen-1-ylcarbamoyl)-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[4-hydroxy-3-(1-isopropyl-2-methyl-propylcarbamoyl)-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[4-hydroxy-3-(6-methoxy-3,4-dihydro-2H-quinoline-1-carbonyl)-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[4-hydroxy-3-(6-methyl-3,4-dihydro-2H-quinoline-1-carbonyl)-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[4-hydroxy-3-(4-isopropyl-benzylcarbamoyl)-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[3-(4-chloro-benzylcarbamoyl)-4-hydroxy-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[4-hydroxy-3-((1R)indan-1-ylcarbamoyl)-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[4-hydroxy-3-((1S)indan-1-ylcarbamoyl)-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[4-hydroxy-3-(1-phenyl-(1R)ethylcarbamoyl)-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[4-hydroxy-3-(1-naphthalen-1-yl-(1S)ethylcarbamoyl)-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[3-(3,4-difluoro-benzylcarbamoyl)-4-hydroxy-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[3-(3-chloro-4-fluoro-benzylcarbamoyl)-4-hydroxy-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[3-(2-chloro-4-fluoro-benzylcarbamoyl)-4-hydroxy-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[4-hydroxy-3-(1-naphthalen-2-yl-(1R)ethylcarbamoyl)-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[3-(2,4-dichloro-benzylcarbamoyl)-4-hydroxy-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[3-(3,4-dichloro-benzylcarbamoyl)-4-hydroxy-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[3-(4-chloro-3-trifluoromethyl-benzylcarbamoyl)-4-hydroxy-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[3-(4-chloro-2-fluoro-benzylcarbamoyl)-4-hydroxy-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-{4-[3-(4-tert-butyl-benzylcarbamoyl)-4-hydroxy-phenoxy]-3,5-dichloro-phenyl}-oxamic acid ethyl ester,
N-[3,5-dichloro-4-(3-cyclohexylcarbamoyl-4-hydroxy-phenoxy)-phenyl]-oxamic acid ethyl ester,
N-[3,5-dichloro-4-(4-hydroxy-3-isopropylcarbamoyl-phenoxy)-phenyl]-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[4-hydroxy-3-(isopropyl-methyl-carbamoyl)-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[3-(cyclopropylmethyl-carbamoyl)-4-hydroxy-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[3-(4-fluoro-benzylcarbamoyl)-4-hydroxy-phenoxy]-phenyl}-oxamic acid,
N-[3,5-dichloro-4-(3-dimethylcarbamoyl-4-hydroxy-phenoxy)-phenyl]-oxamic acid and
N-{3,5-dichloro-4-[4-hydroxy-3-(1-isopropyl-2-methyl-propylamino-carbonyl)-phenoxy]-phenyl}-oxamic acid.
102 . A compound as defined in claim 1 selected from the group consisting of
N-{3,5-dichloro-4-[4-hydroxy-3-(indan-1-ylaminomethyl)-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-{4-[3-(2,3-dihydro-indol-1-ylmethyl)-4-hydroxy-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid ethyl ester,
N-{4-[3-(3,3-dimethyl-piperidin-1-ylmethyl)-4-hydroxy-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid ethyl ester,
N-{4-[4-hydroxy-3-(3-methyl-3-phenyl-piperidin-1-ylmethyl)-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid ethyl ester,
N-{4-[3-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-4-hydroxy-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid ethyl ester,
N-(4-{3-[(4-fluoro-benzylamino)-methyl]-4-hydroxy-phenoxy}-3,5-dimethyl-phenyl)-oxamic acid ethyl ester,
N-(4-{3-[(4-chloro-benzylamino)-methyl]-4-hydroxy-phenoxy}-3,5-dimethyl-phenyl)-oxamic acid ethyl ester,
N-(4-{4-hydroxy-3-[(4-isopropyl-benzylamino)-methyl]-phenoxy}-3,5-dimethyl-phenyl)-oxamic acid ethyl ester,
N-[4-(3-azepan-1-ylmethyl-4-hydroxy-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid ethyl ester,
N-[4-(3-{[(benzo[1,3]dioxol-5-ylmethyl)-amino]-methyl}-4-hydroxy-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid ethyl ester,
N-(4-{4-hydroxy-3-[(1,2,3,4-tetrahydro-naphthalen-1-ylamino)-methyl]-phenoxy}-3,5-dimethyl-phenyl)-oxamic acid ethyl ester,
N-[4-(3-dimethylaminomethyl-4-hydroxy-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid ethyl ester,
N-(4-{4-hydroxy-3-[(methyl-propyl-amino)-methyl]-phenoxy}-3,5-dimethyl-phenyl)-oxamic acid ethyl ester,
N-[4-(3-cyclopropylaminomethyl-4-hydroxy-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid ethyl ester,
N-[4-(4-hydroxy-3-morpholin-4-ylmethyl-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid ethyl ester,
N-(4-{4-hydroxy-3-[(isopropyl-methyl-amino)-methyl]-phenoxy}-3,5-dimethyl-phenyl)-oxamic acid ethyl ester,
N-{4-[4-hydroxy-3-(isopropylamino-methyl)-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid ethyl ester,
N-[4-(3-cyclobutylaminomethyl-4-hydroxy-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid ethyl ester,
N-[4-(3-cyclopentylaminomethyl-4-hydroxy-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid ethyl ester,
N-{3-chloro-4-[3-(3,3-dimethyl-piperidin-1-ylmethyl)-4-hydroxy-phenoxy]-5-methyl-phenyl}-oxamic acid methyl ester,
N-{3-chloro-4-[3-(2,3-dihydro-indol-1-ylmethyl)-4-hydroxy-phenoxy]-5-methyl-phenyl}-oxamic acid methyl ester,
N-(3-chloro-4-{3-[(4-fluoro-benzylamino)-methyl]-4-hydroxy-phenoxy}-5-methyl-phenyl)-oxamic acid ethyl ester,
N-{3-chloro-4-[4-hydroxy-3-(3-methyl-3-phenyl-piperidin-1-ylmethyl)-phenoxy]-5-methyl-phenyl}-oxamic acid ethyl ester,
N-(3-chloro-4-{3-[(4-chloro-benzylamino)-methyl]-4-hydroxy-phenoxy}-5-methyl-phenyl)-oxamic acid ethyl ester,
N-(3-chloro-4-{4-hydroxy-3-[(4-isopropyl-benzylamino)-methyl]-phenoxy}-5-methyl-phenyl)-oxamic acid ethyl ester,
N-{3-chloro-4-[3-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-4-hydroxy-phenoxy]-5-methyl-phenyl}-oxamic acid ethyl ester,
N-[4-(3-azepan-1-ylmethyl-4-hydroxy-phenoxy)-3-chloro-5-methyl-phenyl]-oxamic acid ethyl ester,
N-[4-(3-{[(benzo[1,3]dioxol-5-ylmethyl)-amino]-methyl}-4-hydroxy-phenoxy)-3-chloro-5-methyl-phenyl]-oxamic acid ethyl ester,
N-(3-chloro-4-{4-hydroxy-3-[(1,2,3,4-tetrahydro-naphthalen-1-ylamino)-methyl]-phenoxy}-5-methyl-phenyl)-oxamic acid ethyl ester,
N-[3-chloro-4-(3-dimethylaminomethyl-4-hydroxy-phenoxy)-5-methyl-phenyl]-oxamic acid ethyl ester,
N-(3-chloro-4-{4-hydroxy-3-[(methyl-propyl-amino)-methyl]-phenoxy}-5-methyl-phenyl)-oxamic acid ethyl ester,
N-[3-chloro-4-(3-cyclopropylaminomethyl-4-hydroxy-phenoxy)-5-methyl-phenyl]-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[3-(2,3-dihydro-indol-1-ylmethyl)-4-hydroxy-phenoxy]-phenyl}-oxamic acid methyl ester,
N-{3,5-dichloro-4-[3-(3,3-dimethyl-piperidin-1-ylmethyl)-4-hydroxy-phenoxy]-phenyl}-oxamic acid methyl ester,
N-{3,5-dichloro-4-[4-hydroxy-3-(indan-1-ylaminomethyl)-phenoxy]-phenyl}-oxamic acid methyl ester,
N-{3,5-dichloro-4-[3-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-4-hydroxy-phenoxy]-phenyl}-oxamic acid methyl ester,
N-[4-(3-azepan-1-ylmethyl-4-hydroxy-phenoxy)-3,5-dichloro-phenyl]-oxamic acid methyl ester,
N-(3,5-dichloro-4-{3-[(1-cyclohexyl-(1R)ethylamino)-methyl]-4-hydroxy-phenoxy}-phenyl)-oxamic acid ethyl ester,
N-{4-[3-(bicyclo[2.2.1]hept-2-ylaminomethyl)-4-hydroxy-phenoxy]-3,5-dichloro-phenyl}-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[4-hydroxy-3-(3-methyl-3-phenyl-piperidin-1-ylmethyl)-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-(3,5-dichloro-4-{3-[(4-fluoro-benzylamino)-methyl]-4-hydroxy-phenoxy}-phenyl)-oxamic acid ethyl ester,
N-(3,5-dichloro-4-{4-hydroxy-3-[(1-phenyl-(1R)ethylamino)-methyl]-phenoxy}-phenyl)-oxamic acid ethyl ester,
N-(3,5-dichloro-4-{4-hydroxy-3-[(1-phenyl-(1S)ethylamino)-methyl]-phenoxy}-phenyl)-oxamic acid ethyl ester,
N-[3,5-dichloro-4-(4-hydroxy-3-{[(naphthalen-1-ylmethyl)-amino]-methyl}-phenoxy)-phenyl]-oxamic acid ethyl ester,
N-(3,5-dichloro-4-{4-hydroxy-3-[(1-naphthalen-1-yl-(1R)ethylamino)-methyl]-phenoxy}-phenyl)-oxamic acid ethyl ester,
N-(3,5-dichloro-4-{4-hydroxy-3-[(1,2,3,4-tetrahydro-naphthalen-1-ylamino)-methyl]-phenoxy}-phenyl)-oxamic acid ethyl ester,
N-[3,5-dichloro-4-(3-cyclohexylaminomethyl-4-hydroxy-phenoxy)-phenyl]-oxamic acid ethyl ester,
N-[3,5-dichloro-4-(3-cyclopentylaminomethyl-4-hydroxy-phenoxy)-phenyl]-oxamic acid ethyl ester,
N-[4-(3-{[(benzo[1,3]dioxol-5-ylmethyl)-amino]-methyl}-4-hydroxy-phenoxy)-3,5-dichloro-phenyl]-oxamic acid ethyl ester,
N-(3,5-dichloro-4-{3-[(4-chloro-benzylamino)-methyl]-4-hydroxy-phenoxy}-phenyl)-oxamic acid ethyl ester,
N-(3,5-dichloro-4-{4-hydroxy-3-[(4-isopropyl-benzylamino)-methyl]-phenoxy}-phenyl)-oxamic acid ethyl ester,
N-[3,5-dichloro-4-(4-hydroxy-3-methylaminomethyl-phenoxy)-phenyl]-oxamic acid ethyl ester,
N-[3,5-dichloro-4-(3-cyclopropylaminomethyl-4-hydroxy-phenoxy)-phenyl]-oxamic acid ethyl ester,
N-[3,5-dichloro-4-(4-hydroxy-3-morpholin-4-ylmethyl-phenoxy)-phenyl]-oxamic acid ethyl ester and
N-[3,5-dichloro-4-(3-cyclobutylaminomethyl-4-hydroxy-phenoxy)-phenyl]-oxamic acid ethyl ester.
103 . A compound as defined in claim 1 selected from the group consisting of
N-{4-[4-hydroxy-3-(isopropylmethylcarbamoyl)-phenoxy]-3,5-dimethyl-phenyl}-oxamide,
N-{4-[4-hydroxy-3-(1-isopropyl-2-methyl-propylcarbamoyl)-phenoxy]-3,5-dimethyl-phenyl}-oxamide,
N-[3,5-dichloro-4-(3-cyclohexylcarbamoyl-4-hydroxy-phenoxy)-phenyl]-oxamide,
N-{3-chloro-4-[4-hydroxy-3-(morpholine-4-sulfonyl)-phenoxy]-5-methyl-phenyl}-oxamide,
N-[4-(3-benzenesulfonyl-4-hydroxy-phenoxy)-3,5-dichloro-phenyl]-oxamide,
N-{3-chloro-4-[3-(cyclobutylmethylcarbamoyl)-4-hydroxy-phenoxy]-5-methyl-phenyl}-oxamide,
N-{3-chloro-4-[3-(cyclopropylmethyl-amino-sulfonyl)-4-hydroxy-phenoxy]-5-methyl-phenyl}-oxamide,
N-{3-chloro-4-[4-hydroxy-3-(methylpropylsulfamoyl)-phenoxy]-5-methyl-phenyl}-oxamide,
N-{4-[4-hydroxy-3-(pyrrolidine-1-carbonyl)-phenoxy]-3,5-dimethyl-phenyl}-oxamide,
N-[3-chloro-4-(3-cyclopropylsulfamoyl-4-hydroxy-phenoxy)-5-methyl-phenyl]-oxamide and
N-{4-[3-(cyclobutyl-methyl-carbamoyl)-4-hydroxy-phenoxy]-3,5-dimethyl-phenyl}-oxamide,
104 . A compound as defined in claim 1 selected from the group consisting of
N-{3,5-dichloro-4-[3-(4-chloro-benzenesulfonyl)-4-hydroxy-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[3-(4-chloro-benzenesulfonyl)-4-hydroxy-phenoxy]-phenyl}-oxamic acid,
N-{3-chloro-4-[3-(4-chloro-benzenesulfonyl)-4-hydroxy-phenoxy]-5-methyl-phenyl}-oxamic acid,
N-{3-chloro-4-[3-(4-chloro-benzenesulfonyl)-4-hydroxy-phenoxy]-5-methyl-phenyl}-oxamide,
N-[4-(3-benzenesulfonyl-4-hydroxy-phenoxy)-3,5-dichloro-phenyl]-oxamic acid ethyl ester,
N-[4-(3-benzenesulfonyl-4-hydroxy-phenoxy)-3,5-dichloro-phenyl]-oxamic acid,
N-[4-(3-benzenesulfonyl-4-hydroxy-phenoxy)-3,5-dichloro-phenyl]-oxamide,
N-{3,5-dichloro-4-[4-hydroxy-3-(naphthalene-1-sulfonyl)-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[4-hydroxy-3-(naphthalene-1-sulfonyl)-phenoxy]-phenyl}-oxamic acid,
N-{3,5-dichloro-4-[4-hydroxy-3-(naphthalene-2-sulfonyl)-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[4-hydroxy-3-(naphthalene-2-sulfonyl)-phenoxy]-phenyl}-oxamic acid,
N-{3,5-dichloro-4-[4-hydroxy-3-(toluene-4-sulfonyl)-phenoxy]-phenyl}-oxamic acid and
N-{3,5-dichloro-4-[4-hydroxy-3-(toluene-4-sulfonyl)-phenoxy]-phenyl}-oxamide.
105 . A compound as defined in claim I selected from the group consisting of
N-[3,5-dichloro-4-(3-cyclopropylmethanesulfonyl-4-hydroxy-phenoxy)-phenyl]-oxamic acid ethyl ester, N-[4-(4-hydroxy-3-methanesulfonyl-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid, N-[3,5-dichloro-4-(3-ethanesulfonyl-4-hydroxy-phenoxy)-phenyl]-oxamic acid, N-{3,5-dichloro-4-[4-hydroxy-3-(propane-2-sulfonyl)-phenoxy]-phenyl}-oxamic acid ethyl ester, N-[3,5-dichloro-4-(3-cyclobutylmethanesulfonyl-4-hydroxy-phenoxy)-phenyl]-oxamic acid ethyl ester, N-[3,5-dichloro-4-(3-cyclohexylmethanesulfonyl-4-hydroxy-phenoxy)-phenyl]-oxamic acid ethyl ester, N-[3,5-dichloro-4-(3-cyclopentanesulfonyl-4-hydroxy-phenoxy)-phenyl]-oxamic acid ethyl ester, N-{4-[3-(butane-1-sulfonyl)-4-hydroxy-phenoxy]-3,5-dichloro-phenyl}-oxamic acid, N-[3,5-dichloro-4-(4-hydroxy-3-phenylmethanesulfonyl-phenoxy)-phenyl]-oxamic acid, N-{3,5-dichloro-4-[4-hydroxy-3-(propane-1-sulfonyl)-phenoxy]-phenyl}-oxamic acid, N-{3,5-dichloro-4-[3-(4-fluoro-phenylmethanesulfonyl)-4-hydroxy-phenoxy]-phenyl}-oxamic acid, N-[3,5-dichloro-4-(3-cyclopropylmethanesulfonyl-4-hydroxy-phenoxy)-phenyl]-oxamic acid, N-[3,5-dichloro-4-(3-cyclobutylmethanesulfonyl-4-hydroxy-phenoxy)-phenyl]-oxamic acid and N-[4-(3-cyclopropylmethanesulfonyl-4-hydroxy-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid.
106 . A compound as defined in claim 1 selected from the group consisting of
N-[3,5-dichloro-4-(4-hydroxy-3-phenoxy-phenoxy)-phenyl-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[3-(4-chloro-phenoxy)-4-hydroxy-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[3-(4-chloro-phenoxy)-4-hydroxy-phenoxy]-phenyl}-oxamic acid,
N-[3,5-dichloro-4-(4-hydroxy-3-phenoxy-phenoxy)-phenyl]-oxamic acid,
N-{3,5-dichloro-4-[3-(4-fluoro-phenoxy)-4-hydroxy-phenoxy]-phenyl}-oxamic acid ethyl ester,
N-{3,5-dichloro-4-[3-(4-fluoro-phenoxy)-4-hydroxy-phenoxy]-phenyl}-oxamic acid,
N-{4-[3-(4-fluoro-phenoxy)-4-hydroxy-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid,
N-[4-(4-hydroxy-3-phenoxy-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid and
N-{4-[3-(4-chloro-phenoxy)-4-hydroxy-phenoxy]-3,5-dimethyl-phenyl}-oxamic acid.
107 . A compound as defined in claim 1 selected from the group consisting of
N-[3-chloro-4-(7-hydroxy-2,2-dimethyl-indan-4-yloxy)-5-methyl-phenyl]-oxamic acid,
N-[4-(7-hydroxy-indan-4-yloxy)-3,5-dimethyl-phenyl]-oxamic acid,
N-[3-chloro-4-(7-hydroxy-indan-4-yloxy)-5-methyl-phenyl]-oxamic acid,
N-[4-(7-hydroxy-indan-4-yloxy)-3,5-dimethyl-phenyl]-oxamic acid ethyl ester,
N-[4-(7-hydroxy-indan-4-yloxy)-3,5-dimethyl-phenyl]-oxamide,
N-[3-chloro-4-(7-hydroxy-indan-4-yloxy)-5-methyl-phenyl]-oxamide,
N-[3-chloro-4-(4-hydroxy-5,6,7,8-tetrahydro-naphthalen-1-yloxy)-5-methyl-phenyl]-oxamic acid and
N-[3-chloro-4-(4-hydroxy-5,6,7,8-tetrahydro-naphthalen-1-yloxy)-5-methyl-phenyl]-oxamide.
108 . A compound as defined in claim 1 selected from the group consisting of
N-{3-chloro-4-[3-(4-fluoro-phenoxymethyl)-4-hydroxy-phenoxy]-5-methyl-phenyl}-oxamic acid ethyl ester and
N-[3-chloro-4-(4-hydroxy-3-phenoxymethyl-phenoxy)-5-methyl-phenyl]-oxamic acid ethyl ester.
109 . A compound as defined in claim 1 selected from the group consisting of
N-[3,5-dichloro-4-(1H-indol-5-yloxy)-phenyl]-oxamic acid ethyl ester,
N-[3,5-dichloro-4-(1H-indol-5-yloxy)-phenyl]-oxamic acid ethyl ester,
N-[3,5-dichloro-4-(1H-indol-5-yloxy)-phenyl]-oxamic acid,
N-[3,5-dichloro-4-(1H-indol-5-yloxy)-phenyl]-oxamide,
N-[3-chloro-4-(1H-indol-5-yloxy)-5-methyl-phenyl]-oxamic acid,
N-[3-chloro-4-(1H-indol-5-yloxy)-5-methyl-phenyl]-oxamide,
N-[3,5-dichloro-4-(2-methyl-1H-indol-5-yloxy)-phenyl]-oxamic acid ethyl ester and
N-[3,5-dichloro-4-(2-methyl-1H-indol-5-yloxy)-phenyl]-oxamic acid.
110 . A compound as defined in claim 1 selected from the group consisting of
N-[3,5-dichloro-4-(4-fluoro-3-methyl-phenoxy)-phenyl]-oxamic acid,
N-[4-(4-fluoro-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid,
N-[3,5-dichloro-4-(4-fluoro-phenoxy)-phenyl]-oxamic acid ethyl ester,
N-[3,5-dichloro-4-(3,4-difluoro-phenoxy)-phenyl]-oxamic acid ethyl ester,
N-[3,5-dichloro-4-(3-chloro-4-fluoro-phenoxy)-phenyl]-oxamic acid ethyl ester,
N-[4-(3,4-difluoro-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid,
N-[4-(3-chloro-4-fluoro-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid,
N-[4-(4-fluoro-3-methyl-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid,
N-[3,5-dichloro-4-(4-fluoro-phenoxy)-phenyl]-oxamic acid,
N-[3,5-dichloro-4-(3,4-difluoro-phenoxy)-phenyl]-oxamic acid,
N-[3,5-dichloro-4-(3-chloro-4-fluoro-phenoxy)-phenyl]-oxalamic acid,
N-{4-[3-(cyclobutyl-methyl-carbamoyl)-4-fluoro-phenoxy]-3,5-dimethyl-phenyl}-oxalamic acid ethyl ester,
N-{4-[3-(cyclobutyl-methyl-carbamoyl)-4-fluoro-phenoxy]-3,5-dimethyl-phenyl}-oxalamic acid and
N-[4-(4-fluoro-phenoxy)-3,5-dimethyl-phenyl]-oxalamic acid ethyl ester.
111 . A compound or pharmaceutically acceptable salt as defined in claim 3 wherein R 5 is fluoro.
112 . A compound or pharmaceutically acceptable salt as defined in claim 111 wherein R 4 is hydrogen, fluoro, chloro, methyl or cyclobutyl-methyl-carbamoyl.
113 . A compound or pharmaceutically acceptable salt as defined in claim 112 wherein R 1 and R 2 are each independently methyl or chloro.
114 . A compound or pharmaceutically acceptable salt as defined in claim 113 wherein R 1 and R 2 are each methyl.
115 . A compound or pharmaceutically acceptable salt as defined in claim 113 wherein R 1 and R 2 are each chloro.
116 . A compound or pharmaceutically acceptable salt as defined in claim 113 wherein R 7 is hydrogen, and R 8 is hydrogen or —OR 9 .
117 . A compound or pharmaceutically acceptable salt as defined in claim 116 wherein R 9 is methyl or ethyl.
118 . A compound as defined in claim 1 selected from the group consisting of:
N-[4-(4-fluoro-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid,
N-[3,5-dichloro-4-(4-fluoro-phenoxy)-phenyl]-oxamic acid,
N-[3,5-dichloro-4-(3,4-difluoro-phenoxy)-phenyl]-oxamic acid,
N-[4-(3-methyl-4-Fluoro-phenoxy)-3,5-dichloro-phenyl]-oxamic acid,
N-[3,5-dichloro-4-(3-chloro-4-fluoro-phenoxy)-phenyl]-oxamic acid,
N-[4-(3,4-difluoro-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid,
N-[4-(3-chloro-4-fluoro-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid,
N-[4-(3-methyl-4-fluoro-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid,
N-[3,5-dichloro-4-(4-fluoro-phenoxy)-phenyl]-oxamic acid,
N-[3,5-dichloro-4-(3,4-difluoro-phenoxy)-phenyl]-oxamic acid,
N-{4-[3-(cyclobutyl-methyl-carbamoyl)-4-fluoro-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid and
N-[4-(4-fluoro-phenoxy)-3,5-dimethyl-phenyl]-oxamic acid.
119 . A pharmaceutically acceptable salt of each of said compounds as defined in claim 118 where said salt is independently a potassium salt or a sodium salt.
120 . An ester of each of said compounds as defined in claim 118 where said ester is independently a methyl ester, an ethyl ester or an isopropyl ester.
121 . A method of treating a condition selected from the group consisting of obesity, hyperlipidemia, glaucoma, cardiac arrhythmia, skin disorders, thyroid disease, hypothyroidism, diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression and osteoporosis, in a mammal which comprises administering to said mammal an effective treating amount of a compound, prodrug, isomer or pharmaceutically acceptable salt as defined in claim 1 .
122 . A method as defined in claim 121 further including administering an anorectic agent.
123 . A method as defined in claim 121 further including administering a lipase inhibitor.
124 . A method as defined in claim 122 further including administering a lipase inhibitor.
125 . A method as defined in claim 121 wherein said condition is obesity.
126 . A method as defined in claim 122 wherein said condition is obesity.
127 . A method as defined in claim 123 wherein said condition is obesity.
128 . A method as defined in claim 124 wherein said condition is obesity.
129 . A pharmaceutical composition comprising a compound, prodrug, isomer or pharmaceutically acceptable salt as defined in claim 1 , and a pharmaceutically acceptable vehicle, diluent or carrier.
130 . A pharmaceutical composition as defined in claim 129 further including an anorectic agent.
131 . A pharmaceutical composition as defined in claim 129 further including a lipase inhibitor.
132 . A pharmaceutical composition as defined in claim 130 further including a lipase inhibitor.
133 . A pharmaceutical composition for treating a condition selected from the group consisting of obesity, hyperlipidemia, glaucoma, cardiac arrhythmia, skin disorders, thyroid disease, hypothyroidism, diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression and osteoporosis, in a mammal comprising a compound, prodrug, isomer or pharmaceutically acceptable salt as defined in claim 1 , and a pharmaceutically acceptable vehicle, diluent or carrier.
134 . A pharmaceutical composition as defined in claim 133 further including an anorectic agent.
135 . A pharmaceutical composition as defined in claim 133 further including a lipase inhibitor.
136 . A pharmaceutical composition as defined in claim 134 further including a lipase inhibitor.
137 . A pharmaceutical composition as defined in claim 133 wherein said condition is obesity.
138 . A pharmaceutical composition as defined in claim 134 wherein said condition is obesity.
139 . A pharmaceutical composition as defined in claim 135 wherein said condition is obesity.
148 . A pharmaceutical composition as defined in claim 136 wherein said condition is obesity.
149 . A kit for the treatment of a condition selected from the group consisting of obesity, hyperlipidemia, glaucoma, cardiac arrhythmia, skin disorders, thyroid disease, hypothyroidism, diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression and osteoporosis which comprises: a first compound, said first compound being a compound, prodrug, isomer, or pharmaceutically acceptable salt as defined in claim 1 , and a pharmaceutically acceptable vehicle, carrier or diluent, in a first unit dosage form; a second compound, said second compound being an anorectic agent or a lipase inhibitor, and a pharmaceutically acceptable vehicle, carrier or diluent, in a second unit dosage form; and a container.
150 . A kit as defined in claim 149 wherein said condition is obesity.Join the waitlist — get patent alerts
Track US2003114521A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.